Insights

Roth Capital Raises Price Target On EnteroMedics Following FDA Panel Recommendation

In a research note issued today, Roth Capital analyst Chris Lewis reiterated a Buy rating and boosted his price target on EnteroMedics Inc. (ETRM) to $5.

Roth Capital Reiterates Buy Rating On SolarCity;Raises Price Target to $80

Following SolarCity Corporation (SCTY) announcement that it plans to acquire high-efficiency module manufacturer Silevo for $200mn in a stock-based transaction, Roth Capital analyst Philip Shen …

William Blair Maintains Outperform On TESSCO Technologies Following Discussions With Executives

In a research report issued this morning, William Blair analyst Anil Doradla maintained coverage with a “Market Perform” rating on TESSCO Technologies Incorporated (TESS) following discussions he has held with …

Seeking Alpha Article On Ligand Pharmaceuticals Just Foolish, Says Roth Capital Analyst

A bearish article published Monday afternoon on Seeking Alpha claimed that LGND stock has the potential to lose 100% of its value based …

Galena Reiterated With A Buy At Roth Capital Following Enrollment Completion In Phase IIa Study

In a research note issued earlier today, Roth Capital analyst Joseph Pantginis reiterated coverage with a “Buy” rating on Galena Biopharma, Inc. (GALE), and a …

Roth Capital Reiterates Buy Rating On Can-Fite Following The Completion Of Patients Enrollment

In a research report issued today, Roth Capital analyst Joseph Pantginis reiterated coverage on Can-Fite Bio Pharma (CANF) with a Buy rating and a $28.00 price target.

Roth Capital Sees An Attractive Buying Opportunity In Motorcar Parts of America

In a research note issued today, Roth Capital analyst Philip Shen reiterated coverage with a “Buy” rating on Motorcar Parts of America, Inc. (MPAA), and a …

H.C. Wainwright Keeps ‘Buy’ On Ariad Following $200 Million Offering

In a research note issued today, H.C.

Roth Capital Reiterates Buy Rating On LeMaitre Vascular Following Recent Financing

In a research note issued this morning, Roth Capital analyst Chris Lewis reiterated coverage with a “Buy” rating on LeMaitre Vascular, Inc. (LMAT), and a price target of …

Canaccord Reiterates A Buy On Lannett Company Following FDA Approval For Generic Codeine Sulfate

In a research note issued earlier today, Canaccord analyst John Newman reiterated coverage with a “Buy” rating on Lannett Company, Inc. (LCI), and a …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts